Humanin vs Ipamorelin
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
Humanin
Humanin is a mitochondrial-derived peptide with potent cytoprotective effects. Discovered in 2001, it has shown promise in protecting against age-related diseases including Alzheimer's, cardiovascular disease, and diabetes.
Full details →Ipamorelin
Ipamorelin is a selective growth hormone secretagogue that stimulates the release of growth hormone from the pituitary gland without significantly affecting cortisol or prolactin.
Full details →Side-by-Side Comparison
| Aspect | Humanin | Ipamorelin |
|---|---|---|
| Mechanism | Binds to IGFBP-3 and BAX, inhibiting apoptosis. Activates STAT3 signaling and enhances cellular survival under stress. Protects mitochondrial function and reduces oxidative stress. | Acts as a ghrelin mimetic, binding to the ghrelin receptor (GHS-R) in the pituitary to stimulate GH release. Highly selective with minimal effect on other hormones. |
| Typical Dosage | Research protocols vary widely. Studies have used doses from micrograms to milligrams depending on the analog and route. HNG (S14G-Humanin) is a more potent analog. | Typical dosing ranges from 200-300mcg administered 2-3 times daily, often combined with CJC-1295. |
| Administration | Subcutaneous or intraperitoneal injection in research. Various analogs exist with different potencies and stabilities. | Subcutaneous injection. Best results when administered fasted or before sleep. Often stacked with GHRH peptides. |
| Side Effects | Limited human data. Generally well-tolerated in animal studies. May affect glucose metabolism. | Generally well-tolerated. May cause mild headaches, lightheadedness, or increased hunger initially. |
| Best For |
What They Have in Common
Both Humanin and Ipamorelin are commonly used for: